CVAC — CureVac N.V. Stock Price, Chart & AI Report

Neutral Dec 3, 2025 • 14:01 UTC Benzinga • Globe Newswire

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

BioNTech successfully met the minimum condition for its exchange offer to acquire CureVac, with 81.74% of CureVac shares tendered. The subsequent offering period will continue until December 18, 2025, allowing remaining shareholders to participate.

BNTX CVAC merger acquisition exchange offer biotechnology pharmaceutical

Sentiment note

Being acquired with majority shareholder approval, suggesting a strategic transition rather than a negative outcome

Neutral Aug 4, 2025 • 14:32 UTC Benzinga • Vandana Singh

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

BioNTech reported Q2 sales of $295.7 million, exceeding expectations, with a narrowed per-share loss. The company strengthened its oncology strategy through a collaboration with Bristol Myers Squibb and plans to acquire CureVac.

BNTX BMY CELGR CVAC COVID-19 vaccine oncology mRNA collaboration

Sentiment note

Subject of potential acquisition by BioNTech with uncertain immediate impact

Neutral Jun 20, 2025 • 14:59 UTC GlobeNewswire Inc. • Researchandmarkets.Com

Flu RNA Vaccines Market Research Report 2025-2034 | Global Industry Growth, Competitive Landscape, Opportunities, and Challenges

The global flu RNA vaccines market is expected to grow from $2.78 billion in 2025 to $5.95 billion by 2032, driven by advancements in mRNA technology and the need for rapid adaptation to evolving flu strains. North America leads the market, with notable growth in Europe and Asia-Pacific.

MRNA PFE BNTX CVAC flu RNA vaccines mRNA market growth

Sentiment note

CureVac is mentioned as one of the key players in the flu RNA vaccines market, but the article does not provide specific details about the company's performance or prospects.

Neutral Jun 20, 2025 • 14:57 UTC GlobeNewswire Inc. • N/A

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLP, VERV, CVAC on Behalf of Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating several companies for potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders related to proposed mergers and acquisitions.

CTLP VERV CVAC Cantaloupe Verve Therapeutics CureVac

Sentiment note

The article states that Halper Sadeh LLC is investigating CureVac N.V. for potential violations related to its sale to BioNTech SE, but does not indicate whether the firm believes the terms of the deal are favorable or unfavorable for shareholders.

Neutral Jun 18, 2025 • 18:26 UTC Investing.com • Christine Short

Private-Public Deal Momentum Grows, Yet Megamergers Stay Elusive

While smaller deals have been completed, including overseas acquisitions, the expected surge in large-scale mergers and acquisitions has not materialized. Factors like trade policy uncertainty and economic concerns have kept corporate decision-makers cautious about striking major deals.

CRWV CRCL CHYM DKS M&A IPO Mergers Acquisitions

Sentiment note

CureVac's acquisition by BioNTech is noted, but no sentiment is expressed.

Positive Jun 13, 2025 • 15:41 UTC Investing.com • The Tokenist

BioNTech’s CureVac Deal Signals Deep Pivot Toward mRNA Cancer Therapies

BioNTech has acquired CureVac in a $1.25 billion all-stock deal, marking a strategic pivot for BioNTech towards cancer immunotherapy development using mRNA technology. The transaction aims to strengthen BioNTech's research, development, and commercialization capabilities for mRNA-based cancer treatments.

BNTX CVAC PFE BioNTech CureVac mRNA cancer therapies acquisition

Sentiment note

CureVac shareholders are receiving a substantial 55% premium over the three-month average share price, which is a favorable outcome for the company and its investors.

Positive Jun 12, 2025 • 15:07 UTC Benzinga • Vandana Singh

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

BioNTech has agreed to acquire CureVac in an all-stock transaction valued at around $1.25 billion. The deal aims to strengthen BioNTech's research, development, manufacturing, and commercialization of mRNA-based cancer immunotherapy.

BNTX CVAC BioNTech CureVac mRNA cancer immunotherapy acquisition

Sentiment note

CureVac is being acquired by BioNTech in an all-stock deal, which values the company at around $1.25 billion and provides an opportunity for CureVac's shareholders to benefit from the combined entity's growth.

Positive Jun 12, 2025 • 10:45 UTC Benzinga • Globe Newswire

BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer

BioNTech announced plans to acquire CureVac, a clinical-stage biotech company, in an all-stock transaction. The acquisition aims to strengthen BioNTech's research, development, manufacturing, and commercialization of mRNA-based cancer immunotherapy.

BNTX CVAC BioNTech CureVac mRNA cancer immunotherapy acquisition

Sentiment note

The acquisition of CureVac by BioNTech is seen as a positive move, as it will complement BioNTech's expertise and technologies in mRNA, and the two companies have a shared vision in leveraging mRNA technology for transformative therapies.

Positive Feb 10, 2025 • 16:15 UTC Benzinga • Erica Kollmann

Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch

A Nevada dairy worker has tested positive for the D1.1 strain of bird flu, which was previously associated with a Louisiana man's death in January. The CDC says the public health risk remains low and is monitoring for H5 bird flu activity.

MRNA CVAC GSK NVAX bird flu CDC Nevada poultry industry

Sentiment note

CureVac has started a phase I/II study on its bird flu vaccine candidate developed in collaboration with GSK.

Neutral Dec 8, 2024 • 13:00 UTC GlobeNewswire Inc. • Sns Insider

mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider

The mRNA therapeutics market is expected to grow significantly, driven by the success of mRNA-based COVID-19 vaccines and the expanding applications of mRNA technology in areas like cancer treatment and infectious diseases.

MRNA BNTX CVAC ARCT mRNA Therapeutics Cancer Treatment Infectious Diseases Vaccines

Sentiment note

CureVac is mentioned as one of the major players in the mRNA therapeutics market, but the article does not provide any specific details about the company's performance or growth prospects.

Positive Oct 14, 2024 • 15:48 UTC GlobeNewswire Inc. • Researchandmarkets.Com

mRNA Cancer Vaccines and Therapeutics Research Report 2024 with Long-term Forecasts to 2028 and 2033: Personalized Medicine and Multivalent mRNA Vaccines Lead the Way

The mRNA cancer vaccines and therapeutics market is expected to grow rapidly, from $52.85 billion in 2023 to $113.41 billion in 2028, driven by factors like promising clinical trial results, increased awareness, and advancements in mRNA delivery systems. Key trends include personalized medicine and multivalent mRNA vaccines.

PFE MRK BAYRY NVS mRNA cancer vaccines therapeutics personalized medicine

Sentiment note

CureVac N.V is listed as a major player in the mRNA cancer vaccines and therapeutics market, implying its strong position and ability to capitalize on the market's expansion.

Neutral Aug 27, 2024 • 02:48 UTC GlobeNewswire Inc. • N/A

Simtra BioPharma Solutions ernennt Dr. Lidia Serina zum Head of Development Services

Simtra BioPharma Solutions, a leading CDMO specializing in sterile injectables, has appointed Dr. Lidia Serina as the new Head of Development. Dr. Serina brings over 25 years of experience in the global pharmaceutical industry and has held leadership roles in Europe and North America.

LZAGY CVAC GSK SNY Simtra BioPharma Solutions CDMO sterile injectables Dr. Lidia Serina

Sentiment note

The article briefly mentions that Dr. Serina held a leadership position at Curevac, but does not provide any further details about the company.